PROK Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -7275.65% compared to ProKidney's net margin of 23.32%. ProKidney's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

ProKidney has a consensus price target of $5.60, signalling upside risk potential of 59.09%. On the other hand Johnson & Johnson has an analysts' consensus of $173.66 which suggests that it could grow by 6.55%. Given that ProKidney has higher upside potential than Johnson & Johnson, analysts believe ProKidney is more attractive than Johnson & Johnson.

ProKidney has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

ProKidney has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.08% to investors and pays a quarterly dividend of $1.30 per share. ProKidney pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ProKidney quarterly revenues are $230K, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. ProKidney's net income of -$16.7M is lower than Johnson & Johnson's net income of $5.5B. Notably, ProKidney's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney is -- versus 4.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -7275.65% compared to ProKidney's net margin of 21.63%. ProKidney's return on equity of -- beat Pfizer's return on equity of 8.72%.

ProKidney has a consensus price target of $5.60, signalling upside risk potential of 59.09%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.92%. Given that ProKidney has higher upside potential than Pfizer, analysts believe ProKidney is more attractive than Pfizer.

ProKidney has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

ProKidney has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.92% to investors and pays a quarterly dividend of $0.43 per share. ProKidney pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

ProKidney quarterly revenues are $230K, which are smaller than Pfizer quarterly revenues of $13.7B. ProKidney's net income of -$16.7M is lower than Pfizer's net income of $3B. Notably, ProKidney's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney is -- versus 2.24x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Rallybio has a net margin of -7275.65% compared to ProKidney's net margin of -4452.36%. ProKidney's return on equity of -- beat Rallybio's return on equity of -67.73%.

ProKidney has a consensus price target of $5.60, signalling upside risk potential of 59.09%. On the other hand Rallybio has an analysts' consensus of $1.00 which suggests that it could grow by 119.93%. Given that Rallybio has higher upside potential than ProKidney, analysts believe Rallybio is more attractive than ProKidney.

ProKidney has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rallybio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ProKidney has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rallybio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney pays -- of its earnings as a dividend. Rallybio pays out -- of its earnings as a dividend.

ProKidney quarterly revenues are $230K, which are larger than Rallybio quarterly revenues of $212K. ProKidney's net income of -$16.7M is lower than Rallybio's net income of -$9.4M. Notably, ProKidney's price-to-earnings ratio is -- while Rallybio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney is -- versus 23.88x for Rallybio. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -7275.65% compared to ProKidney's net margin of -1366.49%. ProKidney's return on equity of -- beat Recursion Pharmaceuticals's return on equity of -82.61%.

ProKidney has a consensus price target of $5.60, signalling upside risk potential of 59.09%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.14 which suggests that it could grow by 29.4%. Given that ProKidney has higher upside potential than Recursion Pharmaceuticals, analysts believe ProKidney is more attractive than Recursion Pharmaceuticals.

ProKidney has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ProKidney has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

ProKidney quarterly revenues are $230K, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. ProKidney's net income of -$16.7M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, ProKidney's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney is -- versus 29.16x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.